目前,β受体激动剂在控制哮喘症状中仍是一类很有效的药物,特别在一些新的β_2受体选择性激动剂,如舒喘灵、间羟喘宁、酚丙喘宁等问世后,由于其选择性高、作用强、作用维持时间长、口服有效、不良反应轻等优点,成为哮喘首选的对症治疗药。但是,随着这类药物的广泛应用,尤其在长期应用时,对药物产生耐受性的问题,临床医生在用药时必须加以考虑。对β受体激动剂产生耐受性,指短时间或长期反复应用这类药物而造成对该药的反应性 At present, β-agonists are still a kind of very effective drugs in the control of asthma symptoms, especially in the market of some new selective β_2 receptor agonists such as salbutamol, mecquat and phenprostin Because of its high selectivity, strong role, the role of maintaining a long time, oral effective, mild adverse reactions, asthma has become the preferred symptomatic treatment of drugs. However, with the widespread use of these drugs, especially in long-term use, drug resistance problems, clinicians must be considered in the medication. To β receptor agonist tolerance, refers to repeated short-term or long-term use of such drugs caused by the reactivity of the drug